Heart health marker
This article was originally published in The Gray Sheet
Executive Summary
C-reactive protein is a stronger predictor of cardiovascular events than low-density lipoprotein (LDL) cholesterol, according to a study led by Paul Ridker, MD, Brigham and Women's Hospital in Boston, reported in the Nov. 14 issue of the New England Journal of Medicine. The study followed 27,939 apparently healthy American women for eight years, correlating LDL cholesterol and C-reactive protein levels to incidence of myocardial infarction, ischemic stroke, coronary revascularization and cardiovascular-related death...
You may also be interested in...
CRP test endorsed
American Heart Association and CDC recommend high-sensitivity C-reactive protein testing as an option to facilitate heart disease risk assessment and potential treatment selection when other factors project a 10-year CHD risk of 10%-20%. Published in the Jan. 28 issue of Circulation, guidelines suggest additional studies of the systemic inflammation marker test are needed to clarify appropriate use. A recent 28,000-patient study by Paul Ridker, MD, Brigham and Women's Hospital, Boston, et al., showed the roughly $20 CRP test is a stronger predictor of cardiovascular events than LDL cholesterol ("The Gray Sheet" Nov. 18, 2002, In Brief). CRP test product makers include Bayer, Beckman Coulter, Dade Behring and Diagnostic Products...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.